Joseph David Rosenblatt

Dr. Joseph David Rosenblatt


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2016 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MSMarc Schwartz
Marc Schwartz
YZYu Zhang
Yu Zhang
JRJoseph David Rosenblatt
Joseph David Rosenblatt
The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to calibrate the immune response to malignant cells. Accumulating evidence is pointing to a role for B cells in modulating the immune response to both solid tumors and hematologic cancer. Evidence from murine autoimmune models has defined B regulatory cell (Breg) subsets that express cytokines such as IL-10, TGF-β, and/or express immune regulatory ligands such as PD-L1, which can suppress T cell and/or natural killer cell responses. Multiple murine tumor models exhibit decreased tumor growth in B cell deficient or B cell depleted mice. In several of these models, B cells inhibit T cell mediated tumor immunity and/or facilitate conversion of T cells to CD4+CD25+FoxP3+ T regs, which act to attenuate the innate and/or adaptive antitumor immune response. Mechanisms of suppression include the acquisition of inhibitory ligand expression, and phosphorylation of Stat3, and induction of IL-10 and TGF-β, resulting in a Breg phenotype. Breg suppressive activity may affect diverse cell subtypes, including T effector cells, NK cells, myeloid derived suppressor cells (MDSC) and/or tumor associated macrophages. B cells may also directly promote tumorigenesis through recruitment of inflammatory cells, and upregulation of pro-angiogenic genes and pro-metastatic collagenases. Breg infiltration has now been identified in a variety of solid tumor malignancies including but not limited to ovarian, gastric, non-small cell lung cancer, pancreatic, esophageal, head and neck, and hepatocellular carcinomas. Increasing evidence suggests that recruitment of B cells and acquisition of suppressive activity within the tumor bed may be an important mechanism through which B cells may modulate innate and/or adaptive anti-tumor immunity. B cell depletion in the clinic using anti-CD20 antibodies and/or inhibitors of BTK and/or other signaling pathways, may be a useful strategy for augmenting the anti-tumor immune response.

23 May 2005 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SSSangeeta Shah
Sangeeta Shah
ADAnagha A. Divekar
Anagha A. Divekar
SHShannon P. Hilchey
Shannon P. Hilchey
HCHyun-Mi Cho
Hyun-Mi Cho
CNCorliss L. Newman
Corliss L. Newman
JRJoseph David Rosenblatt
Joseph David Rosenblatt

19 March 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
NBNancy L Bartlett
Nancy L Bartlett
RCRobert Chen
Robert Chen
MFMichelle A Fanale
Michelle A Fanale
PBPauline Brice
Pauline Brice
AGAjay Gopal
Ajay Gopal
AFAndres Forero-Torres
Andres Forero-Torres
Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856).

21 January 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
TTTamar Tadmor
Tamar Tadmor
YZYu Zhang
Yu Zhang
HCHyun-Mi Cho
Hyun-Mi Cho
EPEckhard R. Podack
Eckhard R. Podack
JRJoseph David Rosenblatt
Joseph David Rosenblatt

20 May 2015 in International Immunology
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
NGNicolas Gallastegui
Nicolas Gallastegui
JRJoseph David Rosenblatt
Joseph David Rosenblatt
Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin’s and non-Hodgkin’s lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.

8 July 2012 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YZYu Zhang
Yu Zhang
YEYair Eliav
Yair Eliav
SSSeung-Uon Shin
Seung-Uon Shin
TSTaylor H. Schreiber
Taylor H. Schreiber
EPEckhard R. Podack
Eckhard R. Podack
JRJoseph David Rosenblatt
Joseph David Rosenblatt